BRISTOL-MYERS SQUIBB CO (BMY) Fundamental Analysis & Valuation

NYSE:BMY • US1101221083

59.19 USD
-0.79 (-1.32%)
Last: Mar 12, 2026, 02:18 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BMY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to BMY. BMY was compared to 193 industry peers in the Pharmaceuticals industry. While BMY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. BMY is valued quite cheap, but it does not seem to be growing. Finally BMY also has an excellent dividend rating. This makes BMY very considerable for value and dividend investing!


Dividend Valuation Growth Profitability Health

8

1. BMY Profitability Analysis

1.1 Basic Checks

  • In the past year BMY was profitable.
  • BMY had a positive operating cash flow in the past year.
  • BMY had positive earnings in 4 of the past 5 years.
  • In the past 5 years BMY always reported a positive cash flow from operatings.
BMY Yearly Net Income VS EBIT VS OCF VS FCFBMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B

1.2 Ratios

  • BMY's Return On Assets of 7.83% is amongst the best of the industry. BMY outperforms 89.12% of its industry peers.
  • Looking at the Return On Equity, with a value of 38.19%, BMY belongs to the top of the industry, outperforming 97.41% of the companies in the same industry.
  • BMY has a better Return On Invested Capital (19.52%) than 96.37% of its industry peers.
  • BMY had an Average Return On Invested Capital over the past 3 years of 14.47%. This is in line with the industry average of 13.09%.
  • The 3 year average ROIC (14.47%) for BMY is below the current ROIC(19.52%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.83%
ROE 38.19%
ROIC 19.52%
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
BMY Yearly ROA, ROE, ROICBMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • With an excellent Profit Margin value of 14.64%, BMY belongs to the best of the industry, outperforming 87.05% of the companies in the same industry.
  • In the last couple of years the Profit Margin of BMY has grown nicely.
  • BMY has a better Operating Margin (35.82%) than 95.85% of its industry peers.
  • In the last couple of years the Operating Margin of BMY has grown nicely.
  • Looking at the Gross Margin, with a value of 72.63%, BMY is in the better half of the industry, outperforming 79.79% of the companies in the same industry.
  • BMY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 35.82%
PM (TTM) 14.64%
GM 72.63%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
BMY Yearly Profit, Operating, Gross MarginsBMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BMY Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BMY is creating value.
  • BMY has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BMY has less shares outstanding
  • BMY has a better debt/assets ratio than last year.
BMY Yearly Shares OutstandingBMY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B
BMY Yearly Total Debt VS Total AssetsBMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • BMY has an Altman-Z score of 2.53. This is not the best score and indicates that BMY is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.53, BMY is doing good in the industry, outperforming 66.84% of the companies in the same industry.
  • BMY has a debt to FCF ratio of 3.51. This is a good value and a sign of high solvency as BMY would need 3.51 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 3.51, BMY belongs to the best of the industry, outperforming 89.12% of the companies in the same industry.
  • A Debt/Equity ratio of 2.33 is on the high side and indicates that BMY has dependencies on debt financing.
  • BMY has a Debt to Equity ratio of 2.33. This is in the lower half of the industry: BMY underperforms 77.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.33
Debt/FCF 3.51
Altman-Z 2.53
ROIC/WACC2.22
WACC8.8%
BMY Yearly LT Debt VS Equity VS FCFBMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B 50B

2.3 Liquidity

  • A Current Ratio of 1.26 indicates that BMY should not have too much problems paying its short term obligations.
  • The Current ratio of BMY (1.26) is worse than 75.65% of its industry peers.
  • A Quick Ratio of 1.14 indicates that BMY should not have too much problems paying its short term obligations.
  • BMY has a Quick ratio of 1.14. This is in the lower half of the industry: BMY underperforms 73.06% of its industry peers.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.14
BMY Yearly Current Assets VS Current LiabilitesBMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. BMY Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 439.47% over the past year.
  • BMY shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.92% yearly.
  • Looking at the last year, BMY shows a decrease in Revenue. The Revenue has decreased by -0.22% in the last year.
  • Measured over the past years, BMY shows a small growth in Revenue. The Revenue has been growing by 2.54% on average per year.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%

3.2 Future

  • The Earnings Per Share is expected to decrease by -4.15% on average over the next years.
  • Based on estimates for the next years, BMY will show a decrease in Revenue. The Revenue will decrease by -5.54% on average per year.
EPS Next Y2.98%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
EPS Next 5Y-4.15%
Revenue Next Year-1.84%
Revenue Next 2Y-1.98%
Revenue Next 3Y-5.39%
Revenue Next 5Y-5.54%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BMY Yearly Revenue VS EstimatesBMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
BMY Yearly EPS VS EstimatesBMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. BMY Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 9.62, the valuation of BMY can be described as very reasonable.
  • Based on the Price/Earnings ratio, BMY is valued cheaper than 91.19% of the companies in the same industry.
  • BMY is valuated cheaply when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 9.35 indicates a reasonable valuation of BMY.
  • 89.12% of the companies in the same industry are more expensive than BMY, based on the Price/Forward Earnings ratio.
  • BMY is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.27, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 9.62
Fwd PE 9.35
BMY Price Earnings VS Forward Price EarningsBMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BMY is valued cheaply inside the industry as 92.23% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, BMY is valued cheaper than 90.67% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.38
EV/EBITDA 7.32
BMY Per share dataBMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of BMY may justify a higher PE ratio.
  • BMY's earnings are expected to decrease with -4.05% in the coming years. This may justify a cheaper valuation.
PEG (NY)3.23
PEG (5Y)N/A
EPS Next 2Y0.29%
EPS Next 3Y-4.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. BMY Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 4.15%, BMY is a good candidate for dividend investing.
  • BMY's Dividend Yield is rather good when compared to the industry average which is at 0.71. BMY pays more dividend than 96.37% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, BMY pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.15%

5.2 History

  • On average, the dividend of BMY grows each year by 6.51%, which is quite nice.
  • BMY has been paying a dividend for at least 10 years, so it has a reliable track record.
  • BMY has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)6.51%
Div Incr Years3
Div Non Decr Years3
BMY Yearly Dividends per shareBMY Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • 71.52% of the earnings are spent on dividend by BMY. This is not a sustainable payout ratio.
  • BMY's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP71.52%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
BMY Yearly Income VS Free CF VS DividendBMY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B
BMY Dividend Payout.BMY Dividend Payout, showing the Payout Ratio.BMY Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

BMY Fundamentals: All Metrics, Ratios and Statistics

BRISTOL-MYERS SQUIBB CO

NYSE:BMY (3/12/2026, 2:18:09 PM)

59.19

-0.79 (-1.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)04-30
Inst Owners83.3%
Inst Owner Change1.16%
Ins Owners0.02%
Ins Owner Change0.59%
Market Cap120.54B
Revenue(TTM)48.19B
Net Income(TTM)7.05B
Analysts70.56
Price Target62.03 (4.8%)
Short Float %1.56%
Short Ratio2.28
Dividend
Industry RankSector Rank
Dividend Yield 4.15%
Yearly Dividend2.51
Dividend Growth(5Y)6.51%
DP71.52%
Div Incr Years3
Div Non Decr Years3
Ex-Date01-02
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.39%
Min EPS beat(2)6.92%
Max EPS beat(2)11.85%
EPS beat(4)4
Avg EPS beat(4)18.29%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.75%
EPS beat(12)11
Avg EPS beat(12)12.26%
EPS beat(16)15
Avg EPS beat(16)10.82%
Revenue beat(2)2
Avg Revenue beat(2)1.61%
Min Revenue beat(2)0.79%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)3.42%
Min Revenue beat(4)0.79%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.86%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)12
Avg Revenue beat(16)1.77%
PT rev (1m)6.85%
PT rev (3m)15.57%
EPS NQ rev (1m)1.98%
EPS NQ rev (3m)-3.3%
EPS NY rev (1m)4.07%
EPS NY rev (3m)3.91%
Revenue NQ rev (1m)3.14%
Revenue NQ rev (3m)2.04%
Revenue NY rev (1m)6.67%
Revenue NY rev (3m)6.96%
Valuation
Industry RankSector Rank
PE 9.62
Fwd PE 9.35
P/S 2.5
P/FCF 9.38
P/OCF 8.52
P/B 6.53
P/tB N/A
EV/EBITDA 7.32
EPS(TTM)6.15
EY10.39%
EPS(NY)6.33
Fwd EY10.7%
FCF(TTM)6.31
FCFY10.66%
OCF(TTM)6.95
OCFY11.74%
SpS23.67
BVpS9.07
TBVpS-10.99
PEG (NY)3.23
PEG (5Y)N/A
Graham Number35.43
Profitability
Industry RankSector Rank
ROA 7.83%
ROE 38.19%
ROCE 25.91%
ROIC 19.52%
ROICexc 23.22%
ROICexgc 84.94%
OM 35.82%
PM (TTM) 14.64%
GM 72.63%
FCFM 26.65%
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
ROICexc(3y)17.24%
ROICexc(5y)15.38%
ROICexgc(3y)72.12%
ROICexgc(5y)85.46%
ROCE(3y)19.19%
ROCE(5y)17.14%
ROICexgc growth 3Y-3.78%
ROICexgc growth 5Y13.73%
ROICexc growth 3Y21.19%
ROICexc growth 5Y33.96%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score7
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 2.33
Debt/FCF 3.51
Debt/EBITDA 2.03
Cap/Depr 32.69%
Cap/Sales 2.72%
Interest Coverage 8.22
Cash Conversion 66.54%
Profit Quality 182.1%
Current Ratio 1.26
Quick Ratio 1.14
Altman-Z 2.53
F-Score7
WACC8.8%
ROIC/WACC2.22
Cap/Depr(3y)19.36%
Cap/Depr(5y)15.61%
Cap/Sales(3y)2.66%
Cap/Sales(5y)2.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y2.98%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
EPS Next 5Y-4.15%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-1.84%
Revenue Next 2Y-1.98%
Revenue Next 3Y-5.39%
Revenue Next 5Y-5.54%
EBIT growth 1Y49.54%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year23.75%
EBIT Next 3Y2.42%
EBIT Next 5Y-1.47%
FCF growth 1Y-7.87%
FCF growth 3Y2.44%
FCF growth 5Y-0.69%
OCF growth 1Y-6.81%
OCF growth 3Y2.71%
OCF growth 5Y0.15%

BRISTOL-MYERS SQUIBB CO / BMY FAQ

What is the ChartMill fundamental rating of BRISTOL-MYERS SQUIBB CO (BMY) stock?

ChartMill assigns a fundamental rating of 6 / 10 to BMY.


What is the valuation status for BMY stock?

ChartMill assigns a valuation rating of 8 / 10 to BRISTOL-MYERS SQUIBB CO (BMY). This can be considered as Undervalued.


What is the profitability of BMY stock?

BRISTOL-MYERS SQUIBB CO (BMY) has a profitability rating of 8 / 10.


Can you provide the financial health for BMY stock?

The financial health rating of BRISTOL-MYERS SQUIBB CO (BMY) is 5 / 10.


What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BMY) stock?

The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BMY) is expected to grow by 2.98% in the next year.